BillionToOne
BLLN on Nasdaq. BillionToOne sells prenatal and oncology molecular diagnostics to healthcare providers. Market value $5.3bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't pin down how many shares it has, so we don't rank it.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $1.78 of spare cash in the past 12 months. A savings account pays about $4.
You pay 32.2 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.
$89.92 a share, 45% above its 1-year low
Over the past year the price has ranged from $61.96 to $150.44.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $34 million in the past 12 months, $16 million in the year to December 2025.
| Revenue | |
| Revenue | $305m |
| Operating margin | |
| Operating margin | 5.3% |
| Debt to equity | |
| Debt to equity | 0.12 |
| Shares outstanding | |
| Shares outstanding | 0.02bn |
Health checks
- Free cash flow positive1 of 1 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Not enough data
- Debt0.12× equity
- Revenue growth, five yearsUnknown
- Buying back its own sharesRoughly flat
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $123 million last quarter, up 47% on a year ago.
- Profit: $17 million, up 205% on a year ago.
- 245% more shares than a year ago. Each share owns a bit less of the company.
- It has $472 million more cash than debt, up from $139 million a year ago.
| Quarter to | Amount |
|---|---|
| September 2025 | $84m |
| December 2025 | $96m |
| March 2026 | $108m |
| June 2026 | $109m |
| September 2026 | $123m |
| Quarter to | Amount |
|---|---|
| September 2025 | $6m |
| December 2025 | $6m |
| March 2026 | $18m |
| June 2026 | $8m |
| September 2026 | $17m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 11 March 2026
- Next quarterly (estimated, 10-Q)
- 3 February 2027
Who owns it
3 long-term investors we follow own it, up from 0 last quarter. 156 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Polen CapitalDan Davidowitz | $2m | <0.1% | New |
| First Manhattan Co.First Manhattan partners | $403,373 | <0.1% | New |
| Gotham Asset ManagementJoel Greenblatt | $213,804 | <0.1% | New |
Largest holders overall
- Adams Street Partners$205m
- Price T Rowe Associates$121mAdded
- Baillie Gifford$108mCut
- Vanguard Portfolio Management$101mAdded
- Invesco$100mAdded
- Vanguard Capital Management$96mAdded
- Neuberger Berman Group$92mAdded
- Bamco$89m
- Wasatch Advisors LP$62mAdded
- Millennium Management$51mNew
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Firat IleriPassive investor19.6%Since 6 November 2025
What they said
The Shares reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. The Reporting Persons acquired beneficial ownership of the shares as described in this Schedule 13D for investment purposes and intend to review their…
Read the filing - Firat IleriPassive investorat least 18.6%−1.0 pts(filed with 9 related holders)Since 30 September 2026
- Krishna Kittu Kolluri ("Kolluri")Passive investorat least 10.6%(filed with 7 related holders)Since 7 November 2025
- Oguzhan AtayPassive investor7.3%Since 31 December 2025
- David TsaoPassive investor6.9%Since 31 December 2025
| Holder | Stake | Since | |
|---|---|---|---|
Firat Ileri Passive investor | 19.6% | 6 November 2025 | What they saidThe Shares reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. The Reporting Persons acquired beneficial ownership of the shares as described in this Schedule 13D for investment purposes and intend to review their… Read the filing |
Firat Ileri Passive investor | at least 18.6%−1.0 pts (filed with 9 related holders) | 30 September 2026 | |
Krishna Kittu Kolluri ("Kolluri") Passive investor | at least 10.6% (filed with 7 related holders) | 7 November 2025 | |
Oguzhan Atay Passive investor | 7.3% | 31 December 2025 | |
David Tsao Passive investor | 6.9% | 31 December 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 6 sold $58m, $58m of it under preset trading plans.
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 2 November 2026
- Shares
- 30,335
- Price
- $109.93
- Value
- $3m
- Tsao DavidChief Technology Officer, DirectorSoldunder a preset trading plan
- Date
- 2 November 2026
- Shares
- 20,000
- Price
- $109.24
- Value
- $2m
- ten Bosch John RoderickSVP of Laboratory OperationsSoldunder a preset trading plan
- Date
- 2 November 2026
- Shares
- 2,834
- Price
- $113.17
- Value
- $320,724
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 28 October 2026
- Shares
- 11,000
- Price
- $118.00
- Value
- $1m
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 15 October 2026
- Shares
- 5,150
- Price
- $100.23
- Value
- $516,189
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 14 October 2026
- Shares
- 5,850
- Price
- $98.19
- Value
- $574,386
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 12 October 2026
- Shares
- 19,334
- Price
- $94.31
- Value
- $2m
- Tsao DavidChief Technology Officer, DirectorSoldunder a preset trading plan
- Date
- 5 October 2026
- Shares
- 20,000
- Price
- $108.15
- Value
- $2m
- ten Bosch John RoderickSVP of Laboratory OperationsSoldunder a preset trading plan
- Date
- 5 October 2026
- Shares
- 2,834
- Price
- $105.15
- Value
- $297,995
- Atay OguzhanChairman and CEO, DirectorSoldunder a preset trading plan
- Date
- 28 September 2026
- Shares
- 10,999
- Price
- $120.64
- Value
- $1m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 2 November 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 30,335 | $109.93 | $3m |
| 2 November 2026 | Tsao David Chief Technology Officer, Director | Sold under a preset trading plan | 20,000 | $109.24 | $2m |
| 2 November 2026 | ten Bosch John Roderick SVP of Laboratory Operations | Sold under a preset trading plan | 2,834 | $113.17 | $320,724 |
| 28 October 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 11,000 | $118.00 | $1m |
| 15 October 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 5,150 | $100.23 | $516,189 |
| 14 October 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 5,850 | $98.19 | $574,386 |
| 12 October 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 19,334 | $94.31 | $2m |
| 5 October 2026 | Tsao David Chief Technology Officer, Director | Sold under a preset trading plan | 20,000 | $108.15 | $2m |
| 5 October 2026 | ten Bosch John Roderick SVP of Laboratory Operations | Sold under a preset trading plan | 2,834 | $105.15 | $297,995 |
| 28 September 2026 | Atay Oguzhan Chairman and CEO, Director | Sold under a preset trading plan | 10,999 | $120.64 | $1m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in BillionToOne’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 11 Mar 2026, plus the 10-Q filed 4 Nov 2026 and 5 later 8-Ks.
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026 due to the material weaknesses in our internal control over financial reporting as described below.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026 due to the material weaknesses in our internal control over financial reporting as described below.
From the 10-Q filed 4 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It isn't cheap on profits: 32.2× operating profit.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
A big holder just moved. The deep dive shows what the business is worth.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.